Invitation to the presentation of Recipharm’s interim report for the second quarter 2020

Recipharm AB will publish its interim report for the second quarter 2020 on 27th July at 07:45 am CEST.

The company invites investors, analysts and media to a web conference (in English) on 27th July at 10:00 am CEST, where CEO Thomas Eldered and CFO Tobias Hägglöv will present and comment on the report as well as answer questions.

The report will be available on www.recipharm.com/investor-relations from 7:45 am CET the same day and the presentation from the webcast will be uploaded during the day on the 27th July.

The presentation can be followed live, or afterwards on-demand via the same link.

Click here to participate in the web conference.

Questions may be submitted by dialling below telephone numbers during the conference. If you don’t wish to ask questions by telephone you only need to participate through the link above.

From Sweden: +46 8 566 426 51
From France: + 33 170 750 711
From Germany: +49 691 380 34 30
From India: +91 227 127 96 10
From Israel: +972 372 076 79
From Italy: +39 023 601 38 21
From Portugal: +351 210 609 105

From Spain: +34 935 472 900
From the UK: +44 333 300 08 04
From the USA: +1 631 913 14 22

Pin code for participants:

67679708#

 

For more information, please contact:
ir@recipharm.com, telephone: +46 8 602 52 00

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00

www.recipharm.com

Tags:

About Us

About RecipharmRecipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s annual turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com